Blue Jet Healthcare Limited reported its financial results for the quarter and fiscal year ended March 31, 2026. Despite a challenging fiscal year, the company demonstrated 22% QoQ revenue growth in the fourth quarter, driven by strong sales of Advanced Contrast Media. While annual revenue faced a decline, the company maintains robust demand visibility and is actively expanding its infrastructure, including the new Vizag project and the construction of a new R&D centre in Hyderabad.
Financial Performance Overview
For the fourth quarter ended March 31, 2026 (Q4 FY26), Blue Jet Healthcare reported a revenue from operations of Rs. 2,347 million, representing a 22% increase compared to the previous quarter (Q3 FY26). The quarterly EBITDA stood at Rs. 713 million, with an EBITDA margin of 30%, while the Profit After Tax (PAT) reached Rs. 643 million, reflecting a 60% increase over Q3 FY26.
For the full fiscal year 2026, the company recorded revenue of Rs. 9,473 million. The decline in annual revenue was primarily attributed to lower sales in the Pharma Intermediate (PI) and API segments, although this was partially offset by robust growth in the Contrast Media business.
Segment Insights and Gross Margins
The company’s gross margin for Q4 FY26 improved to 56%, up from 52% in Q3 FY26, driven by a favourable product mix and higher sales of Contrast media intermediates. On an annual basis, gross margins remained stable at 54% compared to 55% in FY25. The company continues to demonstrate high entry barriers in its key product segments, supported by long-term supply contracts and strong client relationships.
Strategic Growth and Business Updates
Blue Jet Healthcare is focused on future-proofing its operations through strategic expansion. Key business updates include:
- Vizag Project: Ground-breaking ceremony completed, and project activities are now underway.
- Hyderabad R&D Centre: Civil construction has commenced, with completion expected on or before September 2026.
- Market Expansion: The company has received trial orders for Advanced Contrast Media from a new Japanese customer.
- PI Segment Recovery: Pharma Intermediate de-stocking and inventory normalization are complete, with expectations for robust revenue contributions from this segment in the coming quarters.
With a healthy cash and treasury investment position of Rs. 3,619 million as of March 31, 2026, the company remains well-positioned to execute its growth strategy of forward integration and R&D infrastructure development.
Source: BSE
